Pooling data from the PROMINENT, REDUCE-IT, and STRENGTH trials, Paul Ridker and C. Michael Gibson discuss the residual inflammatory risks for patients treated with statins.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
